BIO

$373.660.33%-1.255

After Hours: 374.91+1.26 +0.34%

Bio Rad Laboratories Inc (BIO)

Date: O: H: L: C: Vol:

Bio Rad Laboratories Inc stock is traded at $373.66, with a volume of 47,242. It is down -0.33% in the last 24 hours and up +1.22% over the past month. Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Previous Close:

$374.91

Open:

$380.05

24h Volume:

47,242

Relative Volume:

0.21

Market Cap:

$9.99B

Revenue:

$2.59B

Net Income/Loss:

$168.80M

P/E Ratio:

61.51

EPS:

$6.07

Net Cash Flow:

$357.20M

1W Performance:

-2.98%

1M Performance:

+1.22%

6M Performance:

+44.91%

1Y Performance:

+20.16%

1-Day Range:

$371.54$380.92

1-Week Range:

$361.27$390.16

52-Week Range:

$236.73$396.23

Bio Rad Laboratories Inc Stock (BIO) Company Profile

Name

Bio Rad Laboratories Inc

Sector

Healthcare

Industry

Medical Devices

Phone

(510) 724-7000

Address

1000 ALFRED NOBEL DRIVE, HERCULES, USA

Employee

7,450

@BioRadLifeSci

Next Earnings Date

2026-11-04

Latest SEC Filings

SEC

BIO's Discussions on X

Market Cap

Revenue

Net Income

Cash Flow

EPS

Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-26	Resumed	RBC Capital Mkts	Outperform
Apr-07-26	Downgrade	Citigroup	Buy → Neutral
Oct-01-24	Upgrade	Citigroup	Neutral → Buy
Aug-28-24	Initiated	Wells Fargo	Equal Weight
Jun-03-24	Resumed	Jefferies	Hold
Apr-03-24	Downgrade	Citigroup	Buy → Neutral
Dec-07-23	Initiated	UBS	Buy
Jun-16-23	Initiated	Wells Fargo	Overweight
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Aug-25-22	Initiated	Credit Suisse	Outperform
Jan-28-22	Reiterated	Citigroup	Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-17-18	Initiated	Goldman	Buy
Sep-20-18	Initiated	Morgan Stanley	Equal-Weight
Feb-16-18	Downgrade	CL King	Buy → Neutral
Jul-13-17	Initiated	Wells Fargo	Outperform
Jun-28-17	Upgrade	Deutsche Bank	Hold → Buy
Jan-18-17	Initiated	Deutsche Bank	Hold
Oct-13-16	Initiated	CL King	Buy
May-06-15	Reiterated	Jefferies	Buy
Dec-18-09	Initiated	Maxim Group	Buy
Nov-06-09	Initiated	Jefferies & Co	Buy
Jul-17-09	Initiated	Soleil	Buy
Sep-26-07	Initiated	Banc of America Sec	Buy
Feb-23-07	Downgrade	Robert W. Baird	Outperform → Neutral

Bio Rad Laboratories Inc Stock (BIO) Financials Data

Period	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period End Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	2,583.20	2,566.50	2,671.30	2,802.20	2,922.50
Cost of revenue USD (M)	1,243.30	1,187.60	1,244.32	1,234.92	1,281.88
Gross profit USD (M)	1,339.90	1,378.90	1,426.95	1,567.33	1,640.66
Research and development USD (M)	275.60	295.90	247.43	256.89	271.66
Operating expenses USD (M)	-	-	1,089.15	1,084.71	1,151.23
Operating income USD (M)	47.20	269.00	337.80	482.62	489.43
Income before tax USD (M)	995.50	-2,342.50	-850.10	-4,704.27	5,438.15
Income tax expense USD (M)	235.60	-498.30	-212.78	-1,076.74	1,192.25
Net income USD (M)	759.90	-1,844.20	-637.32	-3,627.54	4,245.90
Basic EPS USD/shares	27.87	-65.36	-21.82	-121.79	142.33
Diluted EPS USD/shares	27.85	-	-21.82	-121.79	140.56
Basic weighted shares shares (M)	27.26	28.21	29.21	29.79	29.83
Diluted weighted shares shares (M)	27.28	28.21	29.21	29.79	30.21
Selling, general and administrative USD (M)	844.30	814.00	841.72	827.83	879.57

Bio Rad Laboratories Inc Stock (BIO) Insider Trading

DiVincenzo Jonathan P.Oct 24 '26
President & COO
Transaction
Option Exercise
Cost
$0.00
#Shares
1,869
Value ($)
0
#Shares Total
3,832
EVRAN SEDATOct 20 '26
EVP, Global Supply Chain
Transaction
Option Exercise
Cost
$0.00
#Shares
1,044
Value ($)
0
#Shares Total
4,647
BARRY JAMESSep 06 '26
EVP, President, LSG
Transaction
Option Exercise
Cost
$0.00
#Shares
1,056
Value ($)
0
#Shares Total
2,495
EVRAN SEDATSep 06 '26
EVP, Global Supply Chain
Transaction
Option Exercise
Cost
$0.00
#Shares
864
Value ($)
0
#Shares Total
3,880
Lakkaraju Roop KalyanSep 06 '26
EVP, Chief Financial Officer
Transaction
Option Exercise
Cost
$0.00
#Shares
1,536
Value ($)
0
#Shares Total
4,933
Allison SchwartzSep 06 '26
Director
Transaction
Option Exercise
Cost
$0.00
#Shares
92
Value ($)
0
#Shares Total
1,768
SCHWARTZ NORMAN DSep 06 '26
Chairman & CEO
Transaction
Option Exercise
Cost
$0.00
#Shares
3,455
Value ($)
0
#Shares Total
450,873
ENGELHARDT EVA ANETTESep 06 '26
EVP, President, CDG
Transaction
Option Exercise
Cost
$0.00
#Shares
1,152
Value ($)
0
#Shares Total
2,313
ENLOE COURTNEY CSep 06 '26
EVP, General Counsel & Sec
Transaction
Option Exercise
Cost
$0.00
#Shares
768
Value ($)
0
#Shares Total
1,957
SCHWARTZ NORMAN DSep 05 '26
Chairman & CEO
Transaction
Option Exercise
Cost
$0.00
#Shares
4,109
Value ($)
0
#Shares Total
450,294

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	#Shares Total
DiVincenzo Jonathan P.	President & COO	Oct 24 '26	Option Exercise	$0.00	1,869	3,832
EVRAN SEDAT	EVP, Global Supply Chain	Oct 20 '26	Option Exercise	$0.00	1,044	4,647
BARRY JAMES	EVP, President, LSG	Sep 06 '26	Option Exercise	$0.00	1,056	2,495
EVRAN SEDAT	EVP, Global Supply Chain	Sep 06 '26	Option Exercise	$0.00	864	3,880
Lakkaraju Roop Kalyan	EVP, Chief Financial Officer	Sep 06 '26	Option Exercise	$0.00	1,536	4,933
Allison Schwartz	Director	Sep 06 '26	Option Exercise	$0.00	92	1,768
SCHWARTZ NORMAN D	Chairman & CEO	Sep 06 '26	Option Exercise	$0.00	3,455	450,873
ENGELHARDT EVA ANETTE	EVP, President, CDG	Sep 06 '26	Option Exercise	$0.00	1,152	2,313
ENLOE COURTNEY C	EVP, General Counsel & Sec	Sep 06 '26	Option Exercise	$0.00	768	1,957
SCHWARTZ NORMAN D	Chairman & CEO	Sep 05 '26	Option Exercise	$0.00	4,109	450,294

Bio Rad Laboratories Inc Stock (BIO) Latest News

Oct 31, 2026

Avoiding Lag: Real-Time Signals in (BIO) Movement - Stock Traders Daily

Oct 31, 2026

Oct 30, 2026

BIO.B SEC Filings, May-Sep 2026 - BIO-RAD LABORATORIES, INC. Filing Archive - Stock Titan

Oct 30, 2026

Oct 29, 2026

Bio-Rad Laboratories, Inc. Class B (BIO.B) Q3 2025 Earnings Report - Results, Call & Slides - TipRanks

Oct 29, 2026

Oct 28, 2026

Bio-Rad Laboratories, Inc. Class B (BIO.B) Q1 2026 Earnings Report - Results, Call & Slides - TipRanks

Oct 28, 2026

Bio-Rad Laboratories (BIO) Advances on Restructuring Plans and Margin Improvement Potential, Ariel Appreciation Fund Says - Yahoo Finance

Oct 28, 2026

Oct 27, 2026

Form 4 BIO-RAD LABORATORIES: Jonathan P. DiVincenzo (President & COO) For: 24 October - Investing.com UK

Oct 27, 2026

With awards vesting 25% yearly, Bio-Rad (BIO) COO acquires 1,869 shares. - Stock Titan

Oct 27, 2026

BIO (BIO) vs. TMO and DHR: Can Activist Pressure Close Bio-Rad’s Valuation Discount? - Yahoo Finance

Oct 27, 2026

Oct 22, 2026

Form 4 BIO-RAD LABORATORIES: Sedat Evran (EVP, Global Supply Chain) For: 20 October By Investing.com - Investing.com South Africa

Oct 22, 2026

Sedat Evran Reports Vesting of 1,044 Bio-Rad RSUs with Tax Share Disposal on October 20, 2026 - Kalkine Media

Oct 22, 2026

Oct 21, 2026

Bio-Rad Laboratories, Inc. Class B (BIO.B) Earnings Dates, Call Summary & Reports - TipRanks

Oct 21, 2026

Oct 20, 2026

Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026 - Investing News Network

Oct 14, 2026

Oct 10, 2026

Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily

Oct 10, 2026

Oct 06, 2026

Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates - Zacks Investment Research

Oct 06, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.

Oct 06, 2026

Bio-Rad Reports Second-Quarter 2026 Financial Results - Investing News Network

Oct 06, 2026

Oct 05, 2026

Europe Point of Care Diagnostics Market Size and Forecast, 2021 - 2031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.

Oct 05, 2026

Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.

Oct 05, 2026

Magnetic Beads Market - Global Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.

Oct 05, 2026

Sep 30, 2026